Background
Thai National PMTCT program was started since 2001 to provide antiviral drug for pregnant women to cutting HIV transmission from mother in new born children. 2004 PMTCT policy was revised again to launch a new regimen by adding Nevirapine, and High Active Anti Retroviral Therapy for one whose CD4 count less than 200 cell/microlitre. In late 2006 tail end regimen was added to prevent Nevirapine resistant. Antibody and antigen test were done to confirm HIV infection status of children. This study was designed to find out the factor associated with getting HIV tested of children who was born from infected mother.